A recent investigation explored the real-world impact of a six-month tirzepatide regimen on individuals classified as overweight or obese. This research, detailed in the Journal of Diabetes and Its Complications, specifically examined shifts in body composition, metabolic indicators, and overall body weight among participants.
Tirzepatide's Impact on Body Composition and Metabolic Health
Obesity poses a significant global health challenge, affecting a substantial portion of the population. While traditional lifestyle changes like increased physical activity and dietary modifications are fundamental to managing obesity, maintaining these changes long-term often proves difficult, leading to weight regain. Tirzepatide, a unique dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated considerable efficacy in promoting weight reduction and enhancing metabolic health. Despite the critical role of body composition in obesity treatment, empirical data on tirzepatide's effects on this aspect in real-world settings has been scarce.
The study involved adults from two centers in Palermo, Italy, who were either overweight (BMI ≥ 27 kg/m²) or obese (BMI ≥ 30 kg/m²) and presented with at least one related comorbidity, such as prediabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease, but without type 2 diabetes. Excluded participants included those who became pregnant during the study or had used GLP-1 receptor agonists within the preceding three months. Participants began with a weekly 2.5 mg tirzepatide dose, escalating to 5 mg after four weeks. They also adhered to a low-carbohydrate diet without strict caloric limits and engaged in personalized physical activity programs. Younger, non-comorbid individuals were encouraged to combine aerobic and resistance training, while older participants or those with comorbidities aimed for at least 150 minutes of moderate-intensity aerobic activity weekly. Researchers collected clinical, body composition, laboratory, and anthropometric data at baseline, week 12, and week 24. Anthropometric measurements included BMI, body weight, waist-to-height ratio (WtHR), and waist circumference (WC), with bioelectrical impedance analysis used to determine skeletal muscle mass (SMM), fat-free mass (FFM), and fat mass (FM). Fasting plasma glucose (FPG), fasting insulin levels, and insulin resistance (HOMA-IR) were also assessed. The primary outcome was the change in body weight after 24 weeks, with secondary outcomes encompassing changes in WC, BMI, metabolic markers, and body composition.
Significant Fat Reduction and Muscle Preservation Observed
The study included 122 adults, predominantly female (79.5%), with an average age of 44, largely obese (78%), and non-smokers (93%). A notable proportion of participants had dyslipidemia (15%), hypertension (19%), prediabetes (15.6%), and obstructive sleep apnea (4%). All anthropometric measurements—including BMI, WC, and WtHR—showed significant decreases at both 12 and 24 weeks compared to baseline. Specifically, after 24 weeks, average reductions were 15.7% for BMI, 14.9% for WC, and 15.2% for WtHR.
Progressive and substantial weight loss was observed, with 86% of participants achieving at least a 5% weight reduction by 12 weeks, increasing to 98% by 24 weeks. Reductions of 10%, 15%, and 20% were achieved by increasing proportions of participants over time. Fat mass (FM) saw a significant decline of 35.4% from baseline, while fat-free mass (FFM) decreased by a modest 5.1%, and skeletal muscle mass (SMM) remained stable. The treatment also led to improved insulin sensitivity and glycemic control. Correlation analysis revealed a positive association between reductions in BMI, body weight, and FM with decreases in HOMA-IR and fasting insulin levels, underscoring the metabolic benefits of tirzepatide. However, the study's retrospective nature and lack of a control group mean that the observed effects cannot be solely attributed to tirzepatide, as diet and physical activity interventions were also part of the regimen. The focus on participants who completed the full 24-week follow-up and the predominantly female sample may limit the generalizability of the body composition findings. Further research with diverse populations and longer follow-up periods is warranted to confirm these findings and assess long-term outcomes.